Islets of Langerhans
Adenoma, Islet Cell
Islets of Langerhans Transplantation
Carcinoma
Carcinoma, Islet Cell
Carcinoma, Squamous Cell
Carcinoma, Hepatocellular
Insulin
Carcinoma in Situ
Insulin-Secreting Cells
Carcinoma, Papillary
Islet Amyloid Polypeptide
Diabetes Mellitus, Type 1
Insulinoma
Immunohistochemistry
Glucagon
Pancreas
Pancreatic Neoplasms
Glucagon-Secreting Cells
Carcinoma, Ductal, Breast
Carcinoma, Basal Cell
Glucose
Glucagonoma
Carcinoma, Transitional Cell
Diabetes Mellitus, Experimental
Somatostatin
Carcinoma, Bronchogenic
Carcinoma, Intraductal, Noninfiltrating
Carcinoma, Adenoid Cystic
Pancreatic Ducts
Tumor Markers, Biological
Carcinoma, Small Cell
Pancreatic Polypeptide
Carcinoma, Medullary
Carcinoma, Lobular
Streptozocin
Tumor Cells, Cultured
Carcinoma, Neuroendocrine
Prognosis
Glutamate Decarboxylase
RNA, Messenger
Mice, Inbred NOD
Neoplasm Staging
Autoantibodies
Gene Expression Regulation, Neoplastic
Somatostatin-Secreting Cells
Apoptosis
Carcinoma, Mucoepidermoid
Proinsulin
Reverse Transcriptase Polymerase Chain Reaction
Receptor-Like Protein Tyrosine Phosphatases, Class 8
Carcinoma, Endometrioid
Head and Neck Neoplasms
Cells, Cultured
Carcinoma, Embryonal
Carcinoma, Merkel Cell
Carcinoma, Ductal
Mice, Nude
Lymphatic Metastasis
Ovarian Neoplasms
Mice, Transgenic
Adrenocortical Carcinoma
Immunoenzyme Techniques
Carcinoma, Verrucous
Pancreatic Hormones
Carcinoma, Signet Ring Cell
Neoplasm Metastasis
Neoplasm Proteins
C-Peptide
Cell Division
Cell Survival
Gene Expression
Treatment Outcome
Glucose Tolerance Test
Retrospective Studies
Homeodomain Proteins
Neoplasm Recurrence, Local
Carcinoma, Large Cell
Base Sequence
Molecular Sequence Data
Graft Survival
Hyperplasia
Subrenal Capsule Assay
Disease Progression
Rats, Inbred BB
Apudoma
Laryngeal Neoplasms
Blotting, Western
Neoplasm Transplantation
Survival Rate
Autoantigens
Neoplasms, Multiple Primary
Adenocarcinoma, Follicular
Rats, Wistar
Survival Analysis
Antigens, Neoplasm
Cell Differentiation
Signal Transduction
Vipoma
Adenocarcinoma, Mucinous
Fluorescent Antibody Technique
Diazoxide
Transcription Factors
Precancerous Conditions
Niacinamide
Embryonal Carcinoma Stem Cells
Keratins
Diabetes Mellitus, Type 2
Transfection
Trans-Activators
Promoter Regions, Genetic
Carcinoma, Papillary, Follicular
Mutation
Carcinoma, Non-Small-Cell Lung
Transplantation, Isogeneic
Tumor Suppressor Protein p53
Diabetes Mellitus
Amyloid
Tolbutamide
4-Hydroxyaminoquinoline-1-oxide
Endometrial Neoplasms
Follow-Up Studies
Adenocarcinoma, Clear Cell
Colorectal Neoplasms
Tomography, X-Ray Computed
Gene Expression Regulation
alpha-Fetoproteins
Dose-Response Relationship, Drug
Neoplasms, Experimental
Combined Modality Therapy
Cystadenocarcinoma, Serous
Carcinoma, Lewis Lung
Gene Expression Profiling
Mice, Inbred Strains
Hypoglycemia
Mice, SCID
Autoimmunity
Flow Cytometry
Endocrine Cells
Tissue Array Analysis
Disease-Free Survival
Glucose Transporter Type 2
DNA-Binding Proteins
Calcium
Sensitivity and Specificity
Winged-Helix Transcription Factors
Glucagon-Like Peptide 1
Cisplatin
Cadherins
Liver
Glucokinase
Up-Regulation
Mice, Knockout
Chromogranins
Cell Transformation, Neoplastic
Neuroendocrine Tumors
Rats, Inbred Strains
Biopsy
Receptors, Somatostatin
Cell Count
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. (1/51)
Solid tumors depend on angiogenesis for their growth. In a transgenic mouse model of pancreatic islet cell carcinogenesis (RIP1-Tag2), an angiogenic switch occurs in premalignant lesions, and angiogenesis persists during progression to expansive solid tumors and invasive carcinomas. RIP1-Tag2 mice were treated so as to compare the effects of four angiogenesis inhibitors at three distinct stages of disease progression. AGM-1470, angiostatin, BB-94, and endostatin each produced distinct efficacy profiles in trials aimed at preventing the angiogenic switch in premalignant lesions, intervening in the rapid expansion of small tumors, or inducing the regression of large end-stage cancers. Thus, anti-angiogenic drugs may prove most efficacious when they are targeted to specific stages of cancer. (+info)Cellular composition and anatomic distribution in nonfunctioning pancreatic endocrine tumors: immunohistochemical study of 30 cases. (2/51)
OBJECTIVE: To investigate the cytological pattern and distribution in nonfunctioning pancreatic endocrine tumors. METHODS: Using labeled streptavidin-biotin (LSAB), immunohistochemical staining for insulin, glucagon, somatostatin, pancreatic polypeptide and gastrin was performed on 30 nonfunctioning pancreatic endocrine tumors from 30 patients. The cellular composition and anatomic distribution in these tumors were analyzed. RESULTS: Of 30 tumor tissues, 22 (73.3%) were found to contain cells immunoreactive to 1-4 kinds of peptide hormones; 17 (56.7%) showed positive staining for more than one peptide and up to 4 peptides; and 8 (26.7%) showed negative immunoreaction to all antiserum applied. No tumor was found to contain immunoreactive gastrin. Among 17 multihormonal tumors, 4 contained 2 kinds of peptide hormones, 8 had 3 kinds, and 5 harbored 4 kinds of peptide hormones. In addition, the difference in the number and type of positive endocrine cells between the tumors arising from the head of the pancreas and those arising from the body and tail of the pancreas were statistically significant (P < 0.05). CONCLUSIONS: Immunohistochemically, the high positive rate to peptide hormones suggests that the nonfunctioning pancreatic endocrine tumors are actually not nonfunctioning; they are asymptomatic pancreatic endocrine tumors. Moreover, an uneven distribution of positive endocrine cells in the nonfunctioning pancreas endocrine tumors within the pancreas was identified. (+info)Induction of pancreatic islet cell tumors in rats by repeated intravenous administration of 4-hydroxyaminoquinoline 1-oxide. (3/51)
The inducibility of pancreatic islet cell tumors by administration of 4-hydroxyaminoquinoline 1-oxide (4HAQO) was investigated in male 6-week-old Sprague-Dawley rats. Rats were given 4HAQO intravenously at a weekly dose of 5 mg/kg 4 times (group 1) or a single dose of 10 mg/kg (group 2). Control rats received the vehicle alone (group 3). Fifty-six weeks after the first 4HAQO administration, all surviving animals were killed and the pancreas was examined histopathologically, immunohistochemically and ultrastructurally. The incidences and multiplicities of islet cell tumors in groups 1, 2, and 3 were 52.3% (p < 0.05 vs group 2, p < 0.01 vs group 3), 19.2% and 0%, and 0.70/animal (p < 0.05 vs group 2, p < 0.01 vs group 3), 0.23 and 0, respectively. Islet cell carcinomas were induced only in group 1, accounting for 6/44 (26%) tumors. Islet cell hyperplasias were found in 61.4% (p < 0.05 vs group 3), 42.3% and 10.0% of groups 1, 2, and 3, with multiplicities of 0.95 (p < 0.05 vs groups 2 and 3), 0.54 and 0.20, respectively. As compared with normal islets from control subjects, islet cell tumors showed an increase in the number of insulin positive cells associated with cytological features indicative of enhanced insulin synthesis and secretion, and a decrease in the number of glucagon positive cells without ultrastructural signs of modified secretory activity. Thus our results indicate that repeated intravenous administration of 4HAQO to rats is useful for the induction of islet cell tumors at high incidence. (+info)The effects of ad libitum overfeeding and moderate and marked dietary restriction on age-related spontaneous pancreatic islet pathology in Sprague-Dawley rats. (4/51)
This study compared the effects of ad libitum (AL) overfeeding and moderate or marked dietary restriction (DR) on aged-related degenerative and proliferative changes of the endocrine pancreas in Sprague-Dawley (SD) rats. SD rats were fed Purina Certified Rodent Diet AL (group 1), DR at 72-79% of AL (group 2), DR at 68-72% of AL (group 3) or DR at 47-48% of AL (group 4) for 106 weeks. Interim necropsies were performed at 13, 26, and 53 weeks, after a 7-day 5-bromo-2-deoxyuridine (BrdU)-filled minipump implantation. Before each necropsy, glucose and serum insulin levels were measured. In addition to the routine histopathologic examination performed in both sexes, determination of 9 pancreatic islet stereologic parameters was done in males at 13, 26, and 53 weeks. In AL-fed rats, early changes in the islet morphology occurred, which resulted in a high incidence of islet fibrosis, focal hyperplasias and adenomas by two years. DR was dose-proportionally associated with decreased glucose and serum insulin levels, and delayed the onset, and decreased the incidence and severity of islet fibrosis and hyperplasia. Results of the stereology supported the histopathologic and clinical chemistry findings. It demonstrated that, compared to AL-fed rats, DR-fed rats had smaller pancreas, smaller pancreatic islets, smaller insulin secreting cell volumes, a lower degree of islet fibrosis and a lower islet cell BrdU labeling index, which correlated with a lower incidence of islet adenoma and carcinoma at study termination. Moderate and marked degrees of DR delayed the onset and severity of islet hyperplasia and fibrosis in a temporal- and dose-related manner. In contrast to marked DR, which dramatically prevented these changes, moderate DR delayed but not prevented onset of islet tumors. These findings support the concept that moderate DR results in a better-controlled animal model with a lower incidence or delayed onset of chronic spontaneous endocrine diseases in the rat bioassay. (+info)Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. (5/51)
In a prototypical model of multistage tumorigenesis involving pancreatic islets in RIP1-Tag2 transgenic mice, activation of insulin-like growth factor II (IGF-II) was previously shown to serve as a survival factor that inhibited apoptosis. Now IGF-1R, the receptor tyrosine kinase for IGF-II, has been found to be variably upregulated, first uniformly in dysplastic and angiogenic progenitors and then focally at the margins and in invasive regions of carcinomas. When the levels of IGF-1R were forcibly elevated throughout islet tumorigenesis, progression was accelerated at all stages in the pathway, although apoptosis was not differentially suppressed. Notably, encapsulated tumors were absent; instead, invasive carcinomas with downregulated E-cadherin were prevalent, and the majority of mice had local lymph node metastasis. (+info)Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. (6/51)
Functions of receptor tyrosine kinases implicated in angiogenesis were pharmacologically impaired in a mouse model of pancreatic islet cancer. An inhibitor targeting VEGFRs in endothelial cells (SU5416) is effective against early-stage angiogenic lesions, but not large, well-vascularized tumors. In contrast, a kinase inhibitor incorporating selectivity for PDGFRs (SU6668) is shown to block further growth of end-stage tumors, eliciting detachment of pericytes and disruption of tumor vascularity. Importantly, PDGFRs were expressed only in perivascular cells of this tumor type, suggesting that PDGFR(+) pericytes in tumors present a complimentary target to endothelial cells for efficacious antiangiogenic therapy. Therapeutic regimes combining the two kinase inhibitors (SU5416 and SU6668) were more efficacious against all stages of islet carcinogenesis than either single agent. Combination of the VEGFR inhibitor with another distinctive kinase inhibitor targeting PDGFR activity (Gleevec) was also able to regress late-stage tumors. Thus, combinatorial targeting of receptor tyrosine kinases shows promise for treating multiple stages in tumorigenesis, most notably the often-intractable late-stage solid tumor. (+info)Octreotide-sensitive ectopic ACTH production by islet cell carcinoma with multiple liver metastases. (7/51)
We report a 21-year-old woman with ectopic ACTH syndrome due to islet cell carcinoma with multiple liver metastases. On admission, she showed Cushingoid appearance (moon face, central obesity etc.) and had acute respiratory distress syndrome due to pneumocystis carinii pneumonia. Laboratory examination revealed marked elevations of plasma ACTH (735 pg/ml) and cortisol (145 microg/dl) with a profound hypokalemia (2.0 mEq/l). She was found to have multiple masses in the liver and a solid mass in the tail of pancreas by abdominal computerized tomography scanning. Treatment with octreotide successfully reduced elevated plasma ACTH and cortisol levels, and she received frequent transhepatic arterial embolization and chemotherapy. The primary pancreatic tumor was surgically removed, revealing islet cell carcinoma which contained high content of ACTH (100 microg/g wet weight) and abundantly expressed proopiomelanocortin and somatostatin receptor subtype-2 mRNAs as determined by Northern blot analysis. Postoperatively, she was free from symptoms for almost one year. However, progressive enlargement of multiple liver metastases refractory to chemotherapy led her to decide on total hepatectomy and liver transplantation from her father. After liver transplantation, she remained almost free from symptoms for almost one year. However, metastases developed to the mediastinal and paraaortic lymph nodes as detected by 111[In] pentetreotide scintigraphy. Eleven months after liver transplantation, she was again treated with octreotide and, 16 months after, with metyrapone, both of which were effective in reducing ACTH and cortisol levels, respectively, until she died of acute respiratory failure. This case of a young female patient with ectopic ACTH-producing islet cell carcinoma of the pancreas was quite unique in that she survived for 5 years despite the acute onset and rapid progression of the multiple liver metastases at least in part due to the long-lasting favorable response to octreotide and living-related liver transplantation. (+info)Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. (8/51)
Pancreatic endocrine neoplasms (PENs) are uncommon, generally well-differentiated neoplasms that demonstrate prominent endocrine differentiation. Although the majority of PENs remain localized, malignant spread may occur via lymphatic or hematogenous routes. Angiogenic growth factors, including the vascular endothelial growth factor (VEGF) family, have been implicated in new vessel growth and hematogenous metastases, although this has not been studied in PENs. We therefore examined 19 primary well-differentiated PENs and 7 liver metastases to determine the expression of VEGF-A and its family member VEGF-C by immunolabeling analysis. VEGF-A immunoreactivity was evident only in scattered cells throughout all lesions. VEGF-C, however, demonstrated low-to-moderate expression in primary PENs by semiquantitative histoscore analysis (factor of labeling intensity by percentage of positive cells), with significantly increased expression in liver metastases (mean histoscore indices: primary PEN, 4.7 versus liver metastases, 9.5; Student's t test; P =.002773). Microvascular density of primary PENs and liver metastases did not appear to linearly correlate with VEGF-C expression. Examination of the VEGF-C-specific receptors VEGFR-2/KDR/Flk-1 and VEGFR-3/Flt-4 demonstrated intense endothelial immunoreactivity for VEGFR-2, as well as VEGFR-2 and -3 expression on the majority of neoplastic cells, suggesting a possible role in autocrine/paracrine neoplastic growth regulation. We postulate that the upregulation of VEGF-C may be involved in PEN progression and metastases, although not via a direct proangiogenic mechanism. (+info)Adenomas are typically benign (non-cancerous) growths, but they can sometimes become malignant (cancerous) over time if left untreated. Islet cell tumors are relatively rare, making up only about 5% of all pancreatic tumors. They can occur in anyone, regardless of age or gender, although they are most commonly diagnosed in adults between the ages of 40 and 60.
Symptoms of an adenoma, islet cell can vary depending on the size and location of the tumor, but they may include abdominal pain, weight loss, diabetes, and changes in bowel movements or urination patterns. Treatment options for an adenoma, islet cell depend on the type and stage of the tumor, and may include surgery, chemotherapy, and/or radiation therapy.
In summary, an adenoma, islet cell is a rare type of cancer that develops in the cells of the pancreas, specifically in the islets of Langerhans. It can be benign or malignant, and symptoms can vary depending on the size and location of the tumor. Treatment options depend on the type and stage of the tumor.
There are several subtypes of carcinoma, including:
1. Adenocarcinoma: This type of carcinoma originates in glandular cells, which produce fluids or mucus. Examples include breast cancer, prostate cancer, and colon cancer.
2. Squamous cell carcinoma: This type of carcinoma originates in squamous cells, which are found on the surface layers of skin and mucous membranes. Examples include head and neck cancers, cervical cancer, and anal cancer.
3. Basal cell carcinoma: This type of carcinoma originates in the deepest layer of skin, called the basal layer. It is the most common type of skin cancer and tends to grow slowly.
4. Neuroendocrine carcinoma: This type of carcinoma originates in cells that produce hormones and neurotransmitters. Examples include lung cancer, pancreatic cancer, and thyroid cancer.
5. Small cell carcinoma: This type of carcinoma is a highly aggressive form of lung cancer that spreads quickly to other parts of the body.
The signs and symptoms of carcinoma depend on the location and stage of the cancer. Some common symptoms include:
* A lump or mass
* Pain
* Skin changes, such as a new mole or a change in the color or texture of the skin
* Changes in bowel or bladder habits
* Abnormal bleeding
The diagnosis of carcinoma typically involves a combination of imaging tests, such as X-rays, CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a small sample of tissue for examination under a microscope. Treatment options for carcinoma depend on the location and stage of the cancer and may include surgery, radiation therapy, chemotherapy, or a combination of these.
In conclusion, carcinoma is a type of cancer that originates in epithelial cells and can occur in various parts of the body. Early detection and treatment are important for improving outcomes.
References:
1. American Cancer Society. (2022). Carcinoma. Retrieved from
2. Mayo Clinic. (2022). Carcinoma. Retrieved from
3. MedlinePlus. (2022). Carcinoma. Retrieved from
SCC typically appears as a firm, flat, or raised bump on the skin, and may be pink, red, or scaly. The cancer cells are usually well-differentiated, meaning they resemble normal squamous cells, but they can grow rapidly and invade surrounding tissues if left untreated.
SCC is more common in fair-skinned individuals and those who spend a lot of time in the sun, as UV radiation can damage the skin cells and increase the risk of cancer. The cancer can also spread to other parts of the body, such as lymph nodes or organs, and can be life-threatening if not treated promptly and effectively.
Treatment for SCC usually involves surgery to remove the cancerous tissue, and may also include radiation therapy or chemotherapy to kill any remaining cancer cells. Early detection and treatment are important to improve outcomes for patients with SCC.
There are several risk factors for developing HCC, including:
* Cirrhosis, which can be caused by heavy alcohol consumption, viral hepatitis (such as hepatitis B and C), or fatty liver disease
* Family history of liver disease
* Chronic obstructive pulmonary disease (COPD)
* Diabetes
* Obesity
HCC can be challenging to diagnose, as the symptoms are non-specific and can be similar to those of other conditions. However, some common symptoms of HCC include:
* Yellowing of the skin and eyes (jaundice)
* Fatigue
* Loss of appetite
* Abdominal pain or discomfort
* Weight loss
If HCC is suspected, a doctor may perform several tests to confirm the diagnosis, including:
* Imaging tests, such as ultrasound, CT scan, or MRI, to look for tumors in the liver
* Blood tests to check for liver function and detect certain substances that are produced by the liver
* Biopsy, which involves removing a small sample of tissue from the liver to examine under a microscope
Once HCC is diagnosed, treatment options will depend on several factors, including the stage and location of the cancer, the patient's overall health, and their personal preferences. Treatment options may include:
* Surgery to remove the tumor or parts of the liver
* Ablation, which involves destroying the cancer cells using heat or cold
* Chemoembolization, which involves injecting chemotherapy drugs into the hepatic artery to reach the cancer cells
* Targeted therapy, which uses drugs or other substances to target specific molecules that are involved in the growth and spread of the cancer
Overall, the prognosis for HCC is poor, with a 5-year survival rate of approximately 20%. However, early detection and treatment can improve outcomes. It is important for individuals at high risk for HCC to be monitored regularly by a healthcare provider, and to seek medical attention if they experience any symptoms.
Also known as CIS.
Symptoms of type 1 diabetes can include increased thirst and urination, blurred vision, fatigue, weight loss, and skin infections. If left untreated, type 1 diabetes can lead to serious complications such as kidney damage, nerve damage, and blindness.
Type 1 diabetes is diagnosed through a combination of physical examination, medical history, and laboratory tests such as blood glucose measurements and autoantibody tests. Treatment typically involves insulin therapy, which can be administered via injections or an insulin pump, as well as regular monitoring of blood glucose levels and appropriate lifestyle modifications such as a healthy diet and regular exercise.
Insulinoma is a rare type of pancreatic tumor that produces excess insulin, leading to low blood sugar levels. These tumors are typically benign and can be treated with surgery or medication.
Insulinomas account for only about 5% of all pancreatic neuroendocrine tumors. They usually occur in the head of the pancreas and can cause a variety of symptoms, including:
1. Hypoglycemia (low blood sugar): The excess insulin produced by the tumor can cause blood sugar levels to drop too low, leading to symptoms such as shakiness, dizziness, confusion, and rapid heartbeat.
2. Hyperinsulinism (elevated insulin levels): In addition to hypoglycemia, insulinomas can also cause elevated insulin levels in the blood.
3. Abdominal pain: Insulinomas can cause abdominal pain and discomfort.
4. Weight loss: Patients with insulinomas may experience unexplained weight loss.
5. Nausea and vomiting: Some patients may experience nausea and vomiting due to the hypoglycemia or other symptoms caused by the tumor.
Insulinomas are usually diagnosed through a combination of imaging tests such as CT scans, MRI scans, and PET scans, and by measuring insulin and C-peptide levels in the blood. Treatment options for insulinomas include surgery to remove the tumor, medications to control hypoglycemia and hyperinsulinism, and somatostatin analogs to reduce hormone secretion.
Insulinoma is a rare and complex condition that requires careful management by a multidisciplinary team of healthcare professionals, including endocrinologists, surgeons, and radiologists. With appropriate treatment, most patients with insulinomas can experience long-term remission and improved quality of life.
Liver neoplasms, also known as liver tumors or hepatic tumors, are abnormal growths of tissue in the liver. These growths can be benign (non-cancerous) or malignant (cancerous). Malignant liver tumors can be primary, meaning they originate in the liver, or metastatic, meaning they spread to the liver from another part of the body.
There are several types of liver neoplasms, including:
1. Hepatocellular carcinoma (HCC): This is the most common type of primary liver cancer and arises from the main cells of the liver (hepatocytes). HCC is often associated with cirrhosis and can be caused by viral hepatitis or alcohol abuse.
2. Cholangiocarcinoma: This type of cancer arises from the cells lining the bile ducts within the liver (cholangiocytes). Cholangiocarcinoma is rare and often diagnosed at an advanced stage.
3. Hemangiosarcoma: This is a rare type of cancer that originates in the blood vessels of the liver. It is most commonly seen in dogs but can also occur in humans.
4. Fibromas: These are benign tumors that arise from the connective tissue of the liver (fibrocytes). Fibromas are usually small and do not spread to other parts of the body.
5. Adenomas: These are benign tumors that arise from the glandular cells of the liver (hepatocytes). Adenomas are usually small and do not spread to other parts of the body.
The symptoms of liver neoplasms vary depending on their size, location, and whether they are benign or malignant. Common symptoms include abdominal pain, fatigue, weight loss, and jaundice (yellowing of the skin and eyes). Diagnosis is typically made through a combination of imaging tests such as CT scans, MRI scans, and ultrasound, and a biopsy to confirm the presence of cancer cells.
Treatment options for liver neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Surgery may be an option for some patients with small, localized tumors, while others may require chemotherapy or radiation therapy to shrink the tumor before surgery can be performed. In some cases, liver transplantation may be necessary.
Prognosis for liver neoplasms varies depending on the type and stage of the cancer. In general, early detection and treatment improve the prognosis, while advanced-stage disease is associated with a poorer prognosis.
Pancreatic adenocarcinoma is the most common type of malignant pancreatic neoplasm and accounts for approximately 85% of all pancreatic cancers. It originates in the glandular tissue of the pancreas and has a poor prognosis, with a five-year survival rate of less than 10%.
Pancreatic neuroendocrine tumors (PNETs) are less common but more treatable than pancreatic adenocarcinoma. These tumors originate in the hormone-producing cells of the pancreas and can produce excess hormones that cause a variety of symptoms, such as diabetes or high blood sugar. PNETs are classified into two main types: functional and non-functional. Functional PNETs produce excess hormones and are more aggressive than non-functional tumors.
Other rare types of pancreatic neoplasms include acinar cell carcinoma, ampullary cancer, and oncocytic pancreatic neuroendocrine tumors. These tumors are less common than pancreatic adenocarcinoma and PNETs but can be equally aggressive and difficult to treat.
The symptoms of pancreatic neoplasms vary depending on the type and location of the tumor, but they often include abdominal pain, weight loss, jaundice, and fatigue. Diagnosis is typically made through a combination of imaging tests such as CT scans, endoscopic ultrasound, and biopsy. Treatment options for pancreatic neoplasms depend on the type and stage of the tumor but may include surgery, chemotherapy, radiation therapy, or a combination of these.
Prognosis for patients with pancreatic neoplasms is generally poor, especially for those with advanced stages of disease. However, early detection and treatment can improve survival rates. Research into the causes and mechanisms of pancreatic neoplasms is ongoing, with a focus on developing new and more effective treatments for these devastating diseases.
The exact cause of ductal carcinoma is unknown, but certain risk factors such as family history, genetics, hormone replacement therapy, obesity, and delayed childbearing have been linked to its development. Early detection through mammography and breast self-examination can improve survival rates, which are generally high for women diagnosed with this type of cancer if caught early. Treatment typically involves surgery to remove the tumor (lumpectomy or mastectomy), followed by radiation therapy and/or chemotherapy.
BCC usually appears as a flesh-colored or pink bump, often with small blood vessels on the surface. It may also be flat and scaly, or have a waxy appearance. In rare cases, BCC can grow deep into the skin and cause damage to surrounding tissue.
Although BCC is not as aggressive as other types of skin cancer, such as melanoma, it can still cause significant damage if left untreated. Treatment options for BCC include topical creams, surgical excision, and Mohs microscopic surgery.
Preventative measures against BCC include protecting the skin from the sun, using sunscreen with a high SPF, and avoiding prolonged exposure to UV radiation. Early detection and treatment are key in managing this condition.
Transitional cell carcinoma typically affects older adults, with the average age at diagnosis being around 70 years. Men are more likely to be affected than women, and the risk of developing TCC increases with age and exposure to certain environmental factors such as smoking and exposure to certain chemicals.
The symptoms of TCC can vary depending on the location and stage of the cancer, but may include:
* Blood in the urine (hematuria)
* Painful urination
* Frequent urination
* Pain in the lower abdomen or back
If left untreated, TCC can spread to other parts of the body, including the lymph nodes, liver, and bones. Treatment options for TCC may include surgery, chemotherapy, and immunotherapy, and the prognosis depends on the stage and location of the cancer at the time of diagnosis.
Preventive measures to reduce the risk of developing TCC include maintaining a healthy diet and lifestyle, avoiding smoking and excessive alcohol consumption, and regular screening for bladder cancer. Early detection and treatment can improve the prognosis for patients with TCC.
Types of Experimental Diabetes Mellitus include:
1. Streptozotocin-induced diabetes: This type of EDM is caused by administration of streptozotocin, a chemical that damages the insulin-producing beta cells in the pancreas, leading to high blood sugar levels.
2. Alloxan-induced diabetes: This type of EDM is caused by administration of alloxan, a chemical that also damages the insulin-producing beta cells in the pancreas.
3. Pancreatectomy-induced diabetes: In this type of EDM, the pancreas is surgically removed or damaged, leading to loss of insulin production and high blood sugar levels.
Experimental Diabetes Mellitus has several applications in research, including:
1. Testing new drugs and therapies for diabetes treatment: EDM allows researchers to evaluate the effectiveness of new treatments on blood sugar control and other physiological processes.
2. Studying the pathophysiology of diabetes: By inducing EDM in animals, researchers can study the progression of diabetes and its effects on various organs and tissues.
3. Investigating the role of genetics in diabetes: Researchers can use EDM to study the effects of genetic mutations on diabetes development and progression.
4. Evaluating the efficacy of new diagnostic techniques: EDM allows researchers to test new methods for diagnosing diabetes and monitoring blood sugar levels.
5. Investigating the complications of diabetes: By inducing EDM in animals, researchers can study the development of complications such as retinopathy, nephropathy, and cardiovascular disease.
In conclusion, Experimental Diabetes Mellitus is a valuable tool for researchers studying diabetes and its complications. The technique allows for precise control over blood sugar levels and has numerous applications in testing new treatments, studying the pathophysiology of diabetes, investigating the role of genetics, evaluating new diagnostic techniques, and investigating complications.
The risk factors for developing bronchogenic carcinoma include smoking, exposure to secondhand smoke, exposure to radon gas, asbestos, and certain industrial chemicals, as well as a family history of lung cancer. Symptoms of bronchogenic carcinoma can include coughing, chest pain, difficulty breathing, fatigue, weight loss, and coughing up blood.
Bronchogenic carcinoma is diagnosed through a combination of imaging tests such as chest x-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, as well as biopsy. Treatment options for bronchogenic carcinoma can include surgery, radiation therapy, chemotherapy, or a combination of these. The prognosis for bronchogenic carcinoma is generally poor, with a five-year survival rate of about 18%.
Prevention is the best approach to managing bronchogenic carcinoma, and this includes quitting smoking, avoiding exposure to secondhand smoke and other risk factors, and getting regular screenings if you are at high risk. Early detection and treatment can improve survival rates for patients with bronchogenic carcinoma, so it is important to seek medical attention if symptoms persist or worsen over time.
Intraductal carcinoma may or may not cause symptoms, and is usually detected by a mammogram. Treatment often involves surgery to remove the cancerous cells from the milk ducts. If left untreated, intraductal carcinoma may progress to more advanced breast cancer in some cases.
Intraductal carcinoma accounts for 20% of all breast cancers diagnosed each year in the United States, according to estimates from the American Cancer Society. The condition affects women of all ages, but is most common in postmenopausal women.
This cancer is known for its aggressive behavior and early metastasis to regional lymph nodes, bones, and distant organs such as the liver and lungs. The prognosis is generally poor, with a 5-year survival rate of about 50%. The treatment options include surgery, radiation therapy, and chemotherapy, and the choice of treatment depends on the stage and location of the tumor.
Adenoid cystic carcinoma is also known as adenoid cystic cancer, cylindromatosis, or basaloid squamous cell carcinoma. It is a rare malignancy that requires specialized knowledge and management by head and neck surgeons and oncologists.
Epidemiology:
* Incidence: Small cell carcinoma (SCC) accounts for approximately 10%-15% of all skin cancers, but it is more common in certain populations such as fair-skinned individuals and those with a history of sun exposure.
* Prevalence: The prevalence of SCC is difficult to determine due to its rarity, but it is believed to be more common in certain geographic regions such as Australia and New Zealand.
Clinical features:
* Appearance: Small cell carcinoma usually appears as a firm, shiny nodule or plaque on sun-exposed areas of the skin, such as the face, ears, lips, and hands. It can also occur in other parts of the body, including the mucous membranes.
* Color: The color of SCC can range from pink to red to purple, and it may be covered with a crust or scab.
* Dimensions: SCC usually measures between 1-5 cm in diameter, but it can be larger in some cases.
* Surface: The surface of SCC may be smooth or rough, and it may have a "pearly" appearance due to the presence of small, white, and shiny nodules called "heidlebergs."
Differential diagnosis:
* Other types of skin cancer, such as basal cell carcinoma and squamous cell carcinoma.
* Other diseases that can cause similar symptoms and appearance, such as psoriasis, eczema, and actinic keratosis.
Treatment:
* Surgical excision: Small cell carcinoma is usually treated with surgical excision, which involves removing the tumor and some surrounding tissue.
* Radiation therapy: In some cases, radiation therapy may be used after surgical excision to ensure that all cancer cells are eliminated.
* Topical treatments: For more superficial SCC, topical treatments such as imiquimod cream or podofilox solution may be effective.
Prognosis:
* The prognosis for small cell carcinoma is generally good if it is detected and treated early.
* However, if left untreated, SCC can invade surrounding tissues and organs, leading to serious complications and potentially fatal outcomes.
Complications:
* Invasion of surrounding tissues and organs.
* Spread of cancer cells to other parts of the body (metastasis).
* Scarring and disfigurement.
* Infection and inflammation.
Characteristics of Medullary Carcinoma:
1. Location: Medullary carcinoma typically arises in the inner substance of the breast, near the milk ducts and blood vessels.
2. Growth pattern: The cancer cells grow in a nodular or sheet-like pattern, with a clear boundary between the tumor and the surrounding normal tissue.
3. Cellular features: The cancer cells are typically large and polygonal, with prominent nucleoli and a pale, pinkish cytoplasm.
4. Lymphocytic infiltration: There is often a significant amount of lymphocytic infiltration surrounding the tumor, which can give it a "spiculated" or "heterogeneous" appearance.
5. Grade: Medullary carcinoma is generally a low-grade cancer, meaning that the cells are slow-growing and less aggressive than those of other types of breast cancer.
6. Hormone receptors: Medullary carcinoma is often hormone receptor-positive, meaning that the cancer cells have estrogen or progesterone receptors on their surface.
7. Her2 status: The cancer cells are typically Her2-negative, meaning that they do not overexpress the Her2 protein.
Prognosis and Treatment of Medullary Carcinoma:
The prognosis for medullary carcinoma is generally good, as it tends to be a slow-growing and less aggressive type of breast cancer. The 5-year survival rate for medullary carcinoma is around 80-90%.
Treatment for medullary carcinoma typically involves surgery, such as a lumpectomy or mastectomy, followed by radiation therapy and/or hormone therapy. Chemotherapy is sometimes used in addition to these treatments, especially if the cancer has spread to the lymph nodes or other parts of the body.
It's important for women with medullary carcinoma to work closely with their healthcare team to develop a personalized treatment plan that takes into account their unique needs and circumstances. With appropriate treatment, many women with medullary carcinoma can achieve long-term survival and a good quality of life.
Adenocarcinoma is a term used to describe a variety of different types of cancer that arise in glandular tissue, including:
1. Colorectal adenocarcinoma (cancer of the colon or rectum)
2. Breast adenocarcinoma (cancer of the breast)
3. Prostate adenocarcinoma (cancer of the prostate gland)
4. Pancreatic adenocarcinoma (cancer of the pancreas)
5. Lung adenocarcinoma (cancer of the lung)
6. Thyroid adenocarcinoma (cancer of the thyroid gland)
7. Skin adenocarcinoma (cancer of the skin)
The symptoms of adenocarcinoma depend on the location of the cancer and can include:
1. Blood in the stool or urine
2. Abdominal pain or discomfort
3. Changes in bowel habits
4. Unusual vaginal bleeding (in the case of endometrial adenocarcinoma)
5. A lump or thickening in the breast or elsewhere
6. Weight loss
7. Fatigue
8. Coughing up blood (in the case of lung adenocarcinoma)
The diagnosis of adenocarcinoma is typically made through a combination of imaging tests, such as CT scans, MRI scans, and PET scans, and a biopsy, which involves removing a sample of tissue from the affected area and examining it under a microscope for cancer cells.
Treatment options for adenocarcinoma depend on the location of the cancer and can include:
1. Surgery to remove the tumor
2. Chemotherapy, which involves using drugs to kill cancer cells
3. Radiation therapy, which involves using high-energy X-rays or other particles to kill cancer cells
4. Targeted therapy, which involves using drugs that target specific molecules on cancer cells to kill them
5. Immunotherapy, which involves using drugs that stimulate the immune system to fight cancer cells.
The prognosis for adenocarcinoma is generally good if the cancer is detected and treated early, but it can be more challenging to treat if the cancer has spread to other parts of the body.
Carcinoma, lobular (also known as lobular carcinoma in situ or LCIS) is a type of cancer that originates in the milk-producing glands (lobules) of the breast. It is a precancerous condition that can progress to invasive breast cancer if left untreated.
Precancerous changes occur within the lobules, leading to an abnormal growth of cells that can eventually break through the basement membrane and invade surrounding tissues. The risk of developing invasive breast cancer is increased in individuals with LCIS, especially if there are multiple areas of involvement.
Diagnosis is typically made through a combination of clinical breast examination, mammography, and histopathological analysis of a biopsy sample. Treatment options for LCIS include close surveillance, surgery, or radiation therapy, depending on the extent of the condition and the individual patient's risk factors.
Medical Specialty:
The medical specialty that deals with carcinoma, lobular is breast surgical oncology. Breast surgical oncologists are trained to diagnose and treat all types of breast cancer, including ductal and lobular carcinomas. They work in collaboration with other healthcare professionals, such as radiation oncologists and medical oncologists, to develop a comprehensive treatment plan for each patient.
Other relevant information:
* Lobular carcinoma in situ (LCIS) is a precancerous condition that affects the milk-producing glands (lobules) of the breast.
* It is estimated that 10-15% of all breast cancers are derived from LCIS.
* Women with a history of LCIS have a higher risk of developing invasive breast cancer in the future.
* The exact cause of LCIS is not fully understood, but it is thought to be linked to hormonal and genetic factors.
Definition:
A type of cancer that arises from cells of the neuroendocrine system, which are cells that produce hormones and neurotransmitters. These tumors can occur in various parts of the body, such as the lungs, digestive tract, and pancreas. They tend to grow slowly and can produce excess hormones or neurotransmitters, leading to a variety of symptoms. Carcinoma, neuroendocrine tumors are relatively rare but are becoming more commonly diagnosed.
Synonyms:
* Neuroendocrine carcinoma
* Neuroendocrine tumor
* Carcinoid tumor
Note: The term "carcinoma" refers to a type of cancer that arises from epithelial cells, while the term "neuroendocrine" refers to the fact that these tumors originate in cells of the neuroendocrine system.
Translation:
English: Neuroendocrine carcinoma
German: Neuroendokrines Karzinom
French: Tumeur carcinoïde neuroendocrine
Spanish: Carcinoma neuendocrino
Italian: Carcinoma neuroendocrino
1. Tumor size and location: Larger tumors that have spread to nearby tissues or organs are generally considered more invasive than smaller tumors that are confined to the original site.
2. Cellular growth patterns: The way in which cancer cells grow and divide can also contribute to the overall invasiveness of a neoplasm. For example, cells that grow in a disorganized or chaotic manner may be more likely to invade surrounding tissues.
3. Mitotic index: The mitotic index is a measure of how quickly the cancer cells are dividing. A higher mitotic index is generally associated with more aggressive and invasive cancers.
4. Necrosis: Necrosis, or the death of cells, can be an indication of the level of invasiveness of a neoplasm. The presence of significant necrosis in a tumor is often a sign that the cancer has invaded surrounding tissues and organs.
5. Lymphovascular invasion: Cancer cells that have invaded lymphatic vessels or blood vessels are considered more invasive than those that have not.
6. Perineural invasion: Cancer cells that have invaded nerve fibers are also considered more invasive.
7. Histological grade: The histological grade of a neoplasm is a measure of how abnormal the cancer cells look under a microscope. Higher-grade cancers are generally considered more aggressive and invasive than lower-grade cancers.
8. Immunohistochemical markers: Certain immunohistochemical markers, such as Ki-67, can be used to evaluate the proliferative activity of cancer cells. Higher levels of these markers are generally associated with more aggressive and invasive cancers.
Overall, the degree of neoplasm invasiveness is an important factor in determining the likelihood of the cancer spreading to other parts of the body (metastasizing) and in determining the appropriate treatment strategy for the patient.
Most nasopharyngeal neoplasms are rare and tend to affect children and young adults more frequently than older adults. The most common types of nasopharyngeal neoplasms include:
1. Nasopharyngeal carcinoma (NPC): This is the most common type of malignant nasopharyngeal neoplasm and tends to affect young adults in Southeast Asia more frequently than other populations.
2. Adenoid cystic carcinoma: This is a rare, slow-growing tumor that usually affects the nasopharynx and salivary glands.
3. Metastatic squamous cell carcinoma: This is a type of cancer that originates in another part of the body (usually the head and neck) and spreads to the nasopharynx.
4. Lymphoma: This is a type of cancer that affects the immune system and can occur in the nasopharynx.
5. Benign tumors: These include benign growths such as papillomas, fibromas, and meningiomas.
Symptoms of nasopharyngeal neoplasms can vary depending on the size and location of the tumor but may include:
* Difficulty swallowing
* Nosebleeds
* Headaches
* Facial pain or numbness
* Trouble breathing through the nose
* Hoarseness or voice changes
* Enlarged lymph nodes in the neck
Diagnosis of nasopharyngeal neoplasms usually involves a combination of imaging tests such as CT or MRI scans, endoscopy (insertion of a flexible tube with a camera into the nose and throat), and biopsy (removal of a small sample of tissue for examination under a microscope).
Treatment of nasopharyngeal neoplasms depends on the type, size, location, and stage of the tumor but may include:
* Surgery to remove the tumor
* Radiation therapy to kill cancer cells
* Chemotherapy to kill cancer cells
* Targeted therapy to attack specific molecules on cancer cells
Prognosis for nasopharyngeal neoplasms varies depending on the type and stage of the tumor but in general, early detection and treatment improve the chances of a successful outcome.
There are several types of thyroid neoplasms, including:
1. Thyroid nodules: These are abnormal growths or lumps that can develop in the thyroid gland. Most thyroid nodules are benign (non-cancerous), but some can be malignant (cancerous).
2. Thyroid cancer: This is a type of cancer that develops in the thyroid gland. There are several types of thyroid cancer, including papillary, follicular, and medullary thyroid cancer.
3. Thyroid adenomas: These are benign tumors that develop in the thyroid gland. They are usually non-cancerous and do not spread to other parts of the body.
4. Thyroid cysts: These are fluid-filled sacs that can develop in the thyroid gland. They are usually benign and do not cause any symptoms.
Thyroid neoplasms can be caused by a variety of factors, including genetic mutations, exposure to radiation, and certain medical conditions, such as thyroiditis (inflammation of the thyroid gland).
Symptoms of thyroid neoplasms can include:
* A lump or swelling in the neck
* Pain in the neck or throat
* Difficulty swallowing or breathing
* Hoarseness or voice changes
* Weight loss or fatigue
Diagnosis of thyroid neoplasms usually involves a combination of physical examination, imaging tests (such as ultrasound or CT scans), and biopsies. Treatment depends on the type and severity of the neoplasm, and can include surgery, radiation therapy, and medications.
There are different types of Breast Neoplasms such as:
1. Fibroadenomas: These are benign tumors that are made up of glandular and fibrous tissues. They are usually small and round, with a smooth surface, and can be moved easily under the skin.
2. Cysts: These are fluid-filled sacs that can develop in both breast tissue and milk ducts. They are usually benign and can disappear on their own or be drained surgically.
3. Ductal Carcinoma In Situ (DCIS): This is a precancerous condition where abnormal cells grow inside the milk ducts. If left untreated, it can progress to invasive breast cancer.
4. Invasive Ductal Carcinoma (IDC): This is the most common type of breast cancer and starts in the milk ducts but grows out of them and invades surrounding tissue.
5. Invasive Lobular Carcinoma (ILC): It originates in the milk-producing glands (lobules) and grows out of them, invading nearby tissue.
Breast Neoplasms can cause various symptoms such as a lump or thickening in the breast or underarm area, skin changes like redness or dimpling, change in size or shape of one or both breasts, discharge from the nipple, and changes in the texture or color of the skin.
Treatment options for Breast Neoplasms may include surgery such as lumpectomy, mastectomy, or breast-conserving surgery, radiation therapy which uses high-energy beams to kill cancer cells, chemotherapy using drugs to kill cancer cells, targeted therapy which uses drugs or other substances to identify and attack cancer cells while minimizing harm to normal cells, hormone therapy, immunotherapy, and clinical trials.
It is important to note that not all Breast Neoplasms are cancerous; some are benign (non-cancerous) tumors that do not spread or grow.
There are several types of lung neoplasms, including:
1. Adenocarcinoma: This is the most common type of lung cancer, accounting for approximately 40% of all lung cancers. It is a malignant tumor that originates in the glands of the respiratory tract and can be found in any part of the lung.
2. Squamous cell carcinoma: This type of lung cancer accounts for approximately 25% of all lung cancers and is more common in men than women. It is a malignant tumor that originates in the squamous cells lining the airways of the lungs.
3. Small cell lung cancer (SCLC): This is a highly aggressive form of lung cancer that accounts for approximately 15% of all lung cancers. It is often found in the central parts of the lungs and can spread quickly to other parts of the body.
4. Large cell carcinoma: This is a rare type of lung cancer that accounts for only about 5% of all lung cancers. It is a malignant tumor that originates in the large cells of the respiratory tract and can be found in any part of the lung.
5. Bronchioalveolar carcinoma (BAC): This is a rare type of lung cancer that originates in the cells lining the airways and alveoli of the lungs. It is more common in women than men and tends to affect older individuals.
6. Lymphangioleiomyomatosis (LAM): This is a rare, progressive, and often fatal lung disease that primarily affects women of childbearing age. It is characterized by the growth of smooth muscle-like cells in the lungs and can lead to cysts, lung collapse, and respiratory failure.
7. Hamartoma: This is a benign tumor that originates in the tissue of the lungs and is usually found in children. It is characterized by an overgrowth of normal lung tissue and can be treated with surgery.
8. Secondary lung cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
9. Metastatic cancer: This type of cancer occurs when cancer cells from another part of the body spread to the lungs through the bloodstream or lymphatic system. It is more common in people who have a history of smoking or exposure to other carcinogens.
10. Mesothelioma: This is a rare and aggressive form of cancer that originates in the lining of the lungs or abdomen. It is caused by asbestos exposure and can be treated with surgery, chemotherapy, and radiation therapy.
Lung diseases can also be classified based on their cause, such as:
1. Infectious diseases: These are caused by bacteria, viruses, or other microorganisms and can include pneumonia, tuberculosis, and bronchitis.
2. Autoimmune diseases: These are caused by an overactive immune system and can include conditions such as sarcoidosis and idiopathic pulmonary fibrosis.
3. Genetic diseases: These are caused by inherited mutations in genes that affect the lungs and can include cystic fibrosis and primary ciliary dyskinesia.
4. Environmental diseases: These are caused by exposure to harmful substances such as tobacco smoke, air pollution, and asbestos.
5. Radiological diseases: These are caused by exposure to ionizing radiation and can include conditions such as radiographic breast cancer and lung cancer.
6. Vascular diseases: These are caused by problems with the blood vessels in the lungs and can include conditions such as pulmonary embolism and pulmonary hypertension.
7. Tumors: These can be benign or malignant and can include conditions such as lung metastases and lung cancer.
8. Trauma: This can include injuries to the chest or lungs caused by accidents or other forms of trauma.
9. Congenital diseases: These are present at birth and can include conditions such as bronchopulmonary foregut malformations and congenital cystic adenomatoid malformation.
Each type of lung disease has its own set of symptoms, diagnosis, and treatment options. It is important to seek medical attention if you experience any persistent or severe respiratory symptoms, as early diagnosis and treatment can improve outcomes and quality of life.
The cancer cells of this type are thought to arise from abnormalities in the cells that line the ducts of the salivary glands. These abnormal cells grow and divide uncontrollably, forming a mass that can obstruct the flow of saliva and cause symptoms such as pain, swelling, and difficulty eating or speaking.
Mucoepidermoid carcinoma is typically diagnosed with a combination of imaging studies, such as CT scans, MRI, and PET scans, and a biopsy, where a sample of tissue is removed from the tumor and examined under a microscope for cancer cells. Treatment typically involves surgery to remove the tumor, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells.
Prognosis for this type of cancer is generally good if it is diagnosed early and treated promptly, but it can be challenging to treat if it has spread to other parts of the body.
Example Sentences:
The patient was diagnosed with adenosquamous carcinoma of the lung and underwent surgical resection.
The pathology report revealed that the tumor was an adenosquamous carcinoma, which is a rare type of lung cancer.
Note: Adenosquamous carcinoma is a rare subtype of non-small cell lung cancer (NSCLC), accounting for approximately 1-3% of all lung cancers. It has a more aggressive clinical course and poorer prognosis compared to other types of NSCLC.